Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects

Epilepsia

Volumn 50, Issue 8, 2009, Pages 1850-1859

  Zannikos, Peter ^b   Novak, Gerald ^b   Yao, Caiping ^b   Verhaeghe, Tom ^c   Franc, Monique A ^b   Solanki, Bhavna ^b   Bialer, Meir ^a,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Carisbamate; Japanese and Western healthy subjects; New antiepileptic drug; Pharmacokinetics; RWJ 333369

Indexed keywords

CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; CARISBAMATE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CALIBRATION; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HUMANS; MALE; PHARMACOGENETICS; REFERENCE VALUES; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 68149145489     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02081.x     Document Type: Article

References (22)

1. Bialer M 2005) The pharmacokinetics and interactions of new antiepileptic drugs (AEDs): an overview. Ther Drug Monit 27 : 722 726.
2. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T 2007) Progress report on new antiepileptic drugs: a summary of the eight Eilat Conference (EILAT VIII). Epilepsy Res 73 : 1 52.
3. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS 2009) Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res 83 : 1 43.
4. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, Chowdhury NR 1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333 : 1171 1175.
5. Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, Yao C 2006) Pharmacokinetic interactions study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy subjects. Epilepsia 47 : 1830 1840.
6. Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, Novak G, Bialer M 2007) An interactions study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia 48 : 1328 1338.
7. Desu MM, Raghavarao D 1990) Sample size methodology. Academic Press, New York.
8. FDA 1998) Guidance for industry pharmacokinetics in patients with imparted renal function - study design, data analysis, and impact on doing and labeling. FDA, Drug Information Branch, Center for Drug Evaluation and Research (CDER), May, 1998, Rockville, MD.
9. FDA 2003) Guidance for industry pharmacokinetics in patients with imparted hepatic function: study design, data analysis, and impact on dosing and labeling. FDA, Drug Information Branch, Center for Drug Evaluation and Research (CDER), Clinical Pharmacology, May, 2003, Rockville, MD.
10. FDA 2006) Guidance for Industry Drug Interaction Studies - study design, data analysis, and implications for dosing and labeling. FDA, Drug Information Branch, Center for Drug Evaluation and Research (CDER), Clinical Pharmacology, Rockville, MD.
11. Francois J, Ferrandon A, Koning E, Nehlig A 2005) A new drug RWJ-333369 protects limbic areas in the lithium-pilocarpine model (li-pilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures. Epilepsia 46 (Suppl 8 269 (abstract).
12. Francois J, Boehrer A, Nehlig A 2008) Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia 49 : 393 399.
13. Gibaldi M, Perrier D 1982) Pharmacokinetics. 2nd ed. Marcel Dekker, New York.
14. Grabenstatter HL, Dudek FE 2004) The use of chronic models in antiepileptic drug discovery: the effect of RWJ-333369 on spontaneous motor seizures in rats with kainite-induced epilepsy. Epilepsia 49 doi :.
15. Hurley TD, Edenberg HJ, Bosron WF 1990) Expression and kinetic characterization of variants of human beta 1 beta 1 alcohol dehydrogenase containing substitutions at amino acid 47. J Biol Chem 265 : 16366 16372.
16. Mannens GSJ, Hendrickx J, Janssen CGM, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, Meuldermans W 2007) The absorption, metabolism and excretion of the novel neuromodulator RWJ-333369 in man. Drug Metab Disposit 35 : 554 565.
17. Nehlig A, Rigoulot M-A, Boehrer A 2005) A new drug, RWJ-333369, displays potent antiepileptic properties in genetic models of absence and audiogenic epilepsy. Epilepsia 46 (Suppl 8 215 (abstract).
18. Rogawski MA 2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 : 273 294.
19. Rowland M, Tozer T 1995) Clinical pharmacokinetics. 3rd ed. Williams & Wilkins, Baltimore, U.S.A.
20. White HS, Sirvastava A, Klein B, Zhao B, Choi YM, Lee SJ 2006) The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Epilepsia 47 (Suppl 4 200.
21. Yamaoka K, Nakagawa T, Uno T 1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6 : 547 558.
22. Yao C, Chien S, Doose DR, Novak G, Bialer M 2006) Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 47 : 1822 1829.